Phase II study of aclarubicin in patients with breast cancer previously untreated with adriamycin.
Kerpel-Fronius
S
S
Gyergyay
F
F
Hindy
I
I
Decker
A
A
Sawinsky
I
I
Mechl
Z
Z
Nekulova
M
M
Kolariĉ
K
K
Tomek
R
R
Röthig
J
J
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin; D004317:Doxorubicin